Ebola outbreak prompts Feds to ante up more development funds for BioCryst antiviral

|About: BioCryst Pharmaceutica... (BCRX)|By:, SA News Editor

The National Institute of Allergy and Infectious Diseases (NIAID) exercises additional options to conduct Phase 1 clinical human safety trials and efficacy studies in non-human primates of BioCryst Pharmaceuticals' (BCRX +3.1%) broad-spectrum viral therapeutic, BCX4430, an RNA-dependent RNA polymerase inhibitor that has demonstrated activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

NIAID will pay BioCryst an additional $4.1M to develop BCX4430.